100
HVTN Experience with NIAID’s Vaccine Research Center’s Multiclade, Multigene Preventive HIV Vaccine Approach
Michael Keefer*1, C Morgan2, L Peiperl3, J McElrath2, Z Moodie2, P Wright4, A Duerr2, B Graham5, G Nabel5, L Corey2, and for the NIAID HIV Vaccine Trials Network
1Univ of Rochester, NY, US; 2Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 3San Francisco Dept of Publ Hlth, CA, US; 4Vanderbilt Univ, Nashville, TN, US; and 5Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US
updated abstract to come
|
